BioInvent Reports the Enrollment of First Patient in P-I/IIa Study of BI-1206 + Keytruda for Solid Tumors

 BioInvent Reports the Enrollment of First Patient in P-I/IIa Study of BI-1206 + Keytruda for Solid Tumors

BioInvent Reports the Enrollment of First Patient in P-I/IIa Study of BI-1206 + Keytruda for Solid Tumors

Shots:

  • The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen
  • The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of Keytruda, and part B, which will explore the activity of the combination regimen in patients with advanced lung cancer, melanoma and other types of malignancies
  • The study will be conducted at multiple sites across the US & EU and will assess its antitumoral activity, as well as explore the expression of potential immunological markers that might predict clinical responses. BI-1206 is a mAb targeting FcgRIIb, currently being evaluated in patients with NHL

Click here to read full press release/ article | Ref: BioInvent | Image: Merck

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post